Lexicon Pharmaceuticals Files 8-K Report
Ticker: LXRX · Form: 8-K · Filed: Nov 6, 2025
Sentiment: neutral
Topics: sec-filing, 8-k, corporate-update
Related Tickers: LXRX
TL;DR
Lexicon Pharma dropped an 8-K on Nov 6, 2025 - check it for updates.
AI Summary
On November 6, 2025, Lexicon Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences. No specific financial figures or new events were detailed in the provided excerpt.
Why It Matters
This filing signals that Lexicon Pharmaceuticals has made a significant disclosure to the SEC, which could contain important information for investors regarding the company's operations or financial health.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without immediate indication of negative events or significant financial distress.
Key Players & Entities
- LEXICON PHARMACEUTICALS, INC. (company) — Filer
- November 6, 2025 (date) — Date of Report
- 2445 TECHNOLOGY FOREST BLVD. (location) — Business Address
- THE WOODLANDS, TEXAS (location) — Business Address City and State
FAQ
What specific "Other Events" are being reported by Lexicon Pharmaceuticals on November 6, 2025?
The provided excerpt of the 8-K filing does not detail the specific "Other Events" being reported, only that this item is included in the filing.
What "Financial Statements and Exhibits" are being filed by Lexicon Pharmaceuticals?
The excerpt states that "Financial Statements and Exhibits" are part of the filing, but does not list the specific documents included.
What is the principal executive office address for Lexicon Pharmaceuticals?
The principal executive offices are located at 2445 Technology Forest Blvd., Suite 1100, The Woodlands, Texas 77381.
What is Lexicon Pharmaceuticals' fiscal year end?
Lexicon Pharmaceuticals' fiscal year ends on December 31.
Under which section of the Securities Exchange Act of 1934 is this 8-K report filed?
This 8-K report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 644 words · 3 min read · ~2 pages · Grade level 9.7 · Accepted 2025-11-06 16:57:12
Key Financial Figures
- $0.001 — ich registered Common stock, par value $0.001 LXRX The Nasdaq Capital Market Che
- $0 — , shares of its common stock, par value $0.001, having an aggregate sales price of
- $75,000,000 — aving an aggregate sales price of up to $75,000,000 (the "Shares"), filed a prospectus supp
Filing Documents
- d37543d8k.htm (8-K) — 25KB
- d37543dex51.htm (EX-5.1) — 9KB
- g37543dsp01.jpg (GRAPHIC) — 4KB
- g37543g1104072224689.jpg (GRAPHIC) — 1KB
- 0001193125-25-270020.txt ( ) — 157KB
- lxrx-20251106.xsd (EX-101.SCH) — 3KB
- lxrx-20251106_lab.xml (EX-101.LAB) — 18KB
- lxrx-20251106_pre.xml (EX-101.PRE) — 11KB
- d37543d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d)Exhibits. Exhibit Number Description 5.1 Opinion of Vinson & Elkins L.L.P. 23.1 Consent of Vinson & Elkins L.L.P. (included in Exhibit 5.1). EX-104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Lexicon Pharmaceuticals, Inc. Date: November 6, 2025 By: /s/ Brian T. Crum Brian T. Crum Senior Vice President and General Counsel